Spine Surgery

3
Pipeline Programs
2
Companies
50
Clinical Trials
2 recruiting
2
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
0
0
3
Early DiscoveryClinical DevelopmentMarket

On Market (2)

Approved therapies currently available

M&
BRIDIONApproved
sugammadex
Merck & Co.
intravenous2015
U
SUGAMMADEXApproved
sugammadex
Unknown Company
injection

Competitive Landscape

2 companies ranked by most advanced pipeline stage

M&
Merck & Co.RAHWAY, NJ
1 program
1
sugammadexPhase 45 trials
Active Trials
NCT06136585Recruiting80Est. Dec 2026
NCT06112353Recruiting128Est. Jul 2026
NCT06225466Completed172Est. Sep 2024
+2 more trials
Globus Medical
Globus MedicalAUDUBON, PA
1 program
NuvaMap O.R.N/A1 trial
Active Trials
NCT02606695Completed306Est. Dec 2020

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
Merck & Co.sugammadex
Merck & Co.sugammadex
Merck & Co.sugammadex
Merck & Co.sugammadex
Merck & Co.sugammadex
Merck & Co.sugammadex
Merck & Co.sugammadex
Merck & Co.sugammadex
Merck & Co.sugammadex
Merck & Co.sugammadex
Merck & Co.sugammadex
Merck & Co.sugammadex
Merck & Co.sugammadex
Merck & Co.sugammadex
Merck & Co.sugammadex

Showing 15 of 50 trials with date data

Clinical Trials (50)

Total enrollment: 17,968 patients across 50 trials

Neuromuscular Blockade Comparison for GI-2 Recovery After Bowel Resection

Start: Apr 2024Est. completion: Jul 2026128 patients
Phase 4Recruiting

Muscle Relaxation for Pediatric Adenotonsillectomy

Start: Apr 2024Est. completion: Sep 2024172 patients
Phase 4Completed

Sugammadex vs Neostigmine/Glycopyrrolate on Urinary Retention After Spine Surgery

Start: Aug 2023Est. completion: Jun 2026118 patients
Phase 4Enrolling By Invitation

Applying Best Clinical Practices to Patients at High Risk of Respiratory Complications

Start: Feb 2022Est. completion: May 202512,248 patients
Phase 4Completed

Comparison of Time to Extubation Using Sugammadex or Neostigmine

Start: Apr 2021Est. completion: Jul 202358 patients
Phase 4Completed

Sugammadex To IMprove Bowel Function

Start: Mar 2021Est. completion: Aug 2023120 patients
Phase 4Completed

Efficacy, Safety, and Pharmacokinetics of Sugammadex (MK-8616) for Reversal of Neuromuscular Blockade in Pediatric Participants Aged Birth to <2 Years (MK-8616-169)

Start: Jul 2019Est. completion: Sep 2023145 patients
Phase 4Completed

Impact of Sugammadex vs. Neostigmine Reversal on Post-Operative Recovery and Complications

Start: Jan 2019Est. completion: Oct 2021
Phase 4Completed

Prevention of Postoperative Events Following Reversal With Sugammadex or Neostigmine

Start: Dec 2018Est. completion: Jan 202130 patients
Phase 4Terminated

Efficacy, Safety, and Pharmacokinetics of Sugammadex for Reversal of Neuromuscular Blockade (NMB) in Pediatric Participants (MK-8616-089)

Start: Feb 2018Est. completion: Jan 2020288 patients
Phase 4Completed

A Study to Compare Neostigmine vs Sugammadex in Length of PACU Stay in Patients Undergoing Sleeve Gastrectomy Surgery

Start: Feb 2018Est. completion: Nov 201868 patients
Phase 4Terminated

Efficacy and Safety of Sugammadex Dosed According to Actual Body Weight (ABW) or Ideal Body Weight (IBW) in Reversal of Neuromuscular Blockade (NMB) in Morbidly Obese Participants (MK-8616-146)

Start: Jan 2018Est. completion: Jan 2019207 patients
Phase 4Completed

Safety of Sugammadex for the Reversal of Neuromuscular Blockade in American Society of Anesthesiologists (ASA) Class 3 or 4 Participants (MK-8616-145)

Start: Dec 2017Est. completion: Sep 2019344 patients
Phase 4Completed

Neuromuscular Blockade on Shoulder Pain of Elderly

Start: Nov 2017Est. completion: Oct 2020100 patients
Phase 4Completed

Sugammadex vs. Neostigmine for Neuromuscular Blockade Reversal in Thoracic Surgical Patients

Start: Sep 2017Est. completion: Sep 201992 patients
Phase 4Completed

Investigation of Sugammadex in Outpatient Urological Procedures

Start: Sep 2017Est. completion: Nov 201954 patients
Phase 4Completed

Speed of Recovery of Reversal of Neuromuscular Blockade in Geriatric Patients Undergoing Spine Surgery

Start: May 2017Est. completion: Aug 201840 patients
Phase 4Completed

The Effect of Sugammadex Versus Neostigmine on Postoperative Pulmonary Complications

Start: Jan 2017Est. completion: Apr 2018200 patients
Phase 4Completed

Quality of Recovery After Reversal With Neostigmine or Sugammadex.

Start: Nov 2016Est. completion: Feb 201880 patients
Phase 4Completed

Can Adequacy of Anesthesia Depth and Quality of Recovery be Influenced by the Level of Neuromuscular Blockade?

Start: Sep 2016Est. completion: Jul 201770 patients
Phase 4Completed

Deep vs Moderate Neuromuscular Blockade With Rocuronium in Patients Undergoing Endolaryngeal Procedures

Start: Jun 2016Est. completion: Mar 2018102 patients
Phase 4Completed

Effect of Neuromuscular Blockade on Operating Conditions and Overall Satisfaction During Spinal Surgery

Start: May 2016Est. completion: Feb 201790 patients
Phase 4Completed

Rocuronium + Sugammadex vs. Succinylcholine + Cisatracurium + Neostigmine/Atropine in Obese Participants (MK-8616-104)

Start: Jul 2015Est. completion: Oct 20160
Phase 4Withdrawn

Recovery of Muscle Function After Deep Neuromuscular Block by Means of Diaphragm Ultrasonography

Start: Nov 2014Est. completion: Jul 201758 patients
Phase 4Unknown

CURES: The Effect of Deep Curarisation and Reversal With Sugammadex on Surgical Conditions and Perioperative Morbidity

Start: Apr 2013Est. completion: Jan 201560 patients
Phase 4Completed

A Study Comparing the Use of Deep or Standard Neuromuscular Blockade in Combination With Low or Standard Insufflation Pressures in Participants Undergoing Laparoscopic Cholecystectomy (P07982)

Start: Nov 2012Est. completion: Apr 2014127 patients
Phase 4Completed

Sugammadex Vs Neostigmine in Reversing Neuromuscular Blocks in Outpatient ERCP. A Randomized, Double-Blinded Trial

Start: Jun 2024Est. completion: Dec 202680 patients
Phase 3Recruiting

The POUR (Postoperative Urinary Retention) Study

Start: Apr 2022Est. completion: Sep 2024171 patients
Phase 3Completed

Study of Sugammadex Versus Usual Care on Incidence of Residual Blockade at Post Anesthesia Care Unit Admission (P07981)

Start: Dec 2011Est. completion: Nov 2012154 patients
Phase 3Completed

Comparison of Sugammadex With Neostigmine as Reversal Agents for Rocuronium at Reappearance of T2 (Study P06101)

Start: Feb 2010Est. completion: Aug 2010128 patients
Phase 3Completed

Comparison of 2.0 mg/kg Sugammadex and Neostigmine at Reappearance of T2 in Chinese and European Subjects (Study 19.4.324)(P05768AM1)(COMPLETED)

Start: Jan 2010Est. completion: Sep 2010308 patients
Phase 3Completed

Efficacy and Safety of 4.0 mg/kg Sugammadex at 1-2 PTC in Chinese and European Subjects (Study 19.4.335)(P05775AM1)(COMPLETED)

Start: Jan 2010Est. completion: Aug 2010164 patients
Phase 3Completed

Rocuronium Plus Sugammadex Versus Succinylcholine Alone in Participants Undergoing Short Surgical Procedures (19.4.319)(P05700 AM2)(COMPLETED)

Start: Nov 2008Est. completion: Dec 2009161 patients
Phase 3Completed

Comparison of 4.0 mg/kg Sugammadex at 1-2 Post Tetanic Counts (PTC) in Renal or Control Patients (19.4.328)(P05769)

Start: Sep 2008Est. completion: Mar 201069 patients
Phase 3Completed

Comparison of Sugammadex With Neostigmine During Laparoscopic Cholecystectomy or Appendectomy (P05699)

Start: Jul 2008Est. completion: May 2009140 patients
Phase 3Completed

Comparison of Sugammadex Administered at 1-2 Post Tetanic Counts (PTCs) or Better With Neostigmine Administered as Per Standard of Care to Reverse Rocuronium-Induced Neuromuscular Blockade in Adults Undergoing Elective Open Abdominal Procedure (19.4.334) (P05774)

Start: May 2008Est. completion: Sep 2008100 patients
Phase 3Completed

Dialysis of Sugammadex in Participants With Severe Renal Impairment (Study 19.4.333) (P05773)

Start: Apr 2008Est. completion: Jul 20096 patients
Phase 3Completed

Relation Between TOF-Watch® SX and a Peripheral Nerve Stimulator After 4.0 mg.Kg-1 Sugammadex (P05698)

Start: Sep 2007Est. completion: Feb 200891 patients
Phase 3Completed

Sugammadex After Continuous Infusion of Rocuronium During Sevoflurane and Propofol Anesthesia (P05949; MK-8616-028)

Start: Dec 2006Est. completion: Mar 200752 patients
Phase 3Completed

Comparison of Recovery From Rocuronium 1.2 mg/kg Followed by Sugammadex (Org 25969) 16 mg/kg at 3 Minutes With Recovery From Succinylcholine 1.0 mg/kg (19.4.303)(P05946)(MK-8616-026)

Start: Feb 2006Est. completion: Sep 2006115 patients
Phase 3Completed

Comparison of the Efficacy, Safety, and Pharmacokinetics of Sugammadex (MK-8616; Org 25969) in Elderly Participants With Adult Participants (MK-8616-029)

Start: Dec 2005Est. completion: Oct 2006162 patients
Phase 3Completed

Comparison of Sugammadex (MK-8616/Org 25969) With Neostigmine Administered at 1-2 Post-tetanic Counts (PTCs) After Administration of Rocuronium or Vecuronium (19.4.302/P05945/MK-8616-025)

Start: Nov 2005Est. completion: Jan 2007182 patients
Phase 3Completed

Comparison of Sugammadex (Org 25969) With Neostigmine as Reversal Agents for Rocuronium or Vecuronium at Reappearance of T2 (P05960)

Start: Nov 2005Est. completion: Mar 2006198 patients
Phase 3Completed

Comparison of Rocuronium and Org 25969 With Cisatracurium and Neostigmine (19.4.310)(P05931)

Start: Nov 2005Est. completion: Aug 200684 patients
Phase 3Completed

Use of Sugammadex at the End of Case in Routine Anesthesia (MK-8616-023)

Start: Oct 2005Est. completion: May 2006224 patients
Phase 3Completed

Safety and Efficacy of Sugammadex (Org 25969, MK-8616) in Participants With or Having a Past History of Pulmonary Disease (19.4.308) (P05932) (MK-8616-017)

Start: Oct 2005Est. completion: Sep 200686 patients
Phase 3Completed

Efficacy, Pharmacokinetics and Safety of Org 25969 in Subjects With Normal or Impaired Renal Function (19.4.304)(P05948)(COMPLETED)

Start: Jun 2005Est. completion: Apr 200630 patients
Phase 3Completed

Redesigned Process in the Operating Room

Start: May 2018Est. completion: Oct 2020120 patients
Phase 2/3Completed

Comparison Of Rocuronium Reversal By Sugammadex To Succinylcholine For Electroconvulsive Therapy (ECT)

Start: Jan 2019Est. completion: Apr 202244 patients
Phase 2Completed

A Bridging Trial Comparing Sugammadex (Org 25969) at 1-2 Post-Tetanic Count (PTC) in Japanese Participants. Part A (P05957)

Start: Dec 2005Est. completion: Oct 2006100 patients
Phase 2Completed

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

2 actively recruiting trials targeting 17,968 patients
2 companies competing in this space